Database : HANSEN Search on : TALIDOMIDA/ADMIN [Subject descriptor] References found : 11 [refine] Displaying: 1 .. 11   in format [Detailed]

page 1 de 1

1 / 11

HANSEN

select to print

Id: 18429 Author: Teo, Steve K; Denny, Kevin H; Stirling, David I; Thomas, Steve D; Morseth, Sandy; Hoberman, Alan M Title: Effects of thalidomide on developmental, peri- and postnatal function in female New Zealand whith rabbits and offspring ..- Source: s.l; s.n; 2004. 11 p. tab. Abstract: The present study determined effects of thalidomide on three successive generations of New Zeland Whith rabbits after oral dosing to FO maternal rabbits during the later third of gestation (post major organogenesis) and lactation. On hundred and twenty four time-mated FO rabbits (31/dose) were gaveged with 0,030,150, or 500mg/kg thalidomide from gestation day 18 (DG 18) to lactation day 28 (DP or day postpartum 28) for approximately 42 days. At 6 months, 12 F1 females were randomly paired witthin each dose group and mated. Reproductive evaluation and/or gross necropsy of the thoracic, abodominal, and pelvic viscera was perfomed on day 29 postpartum (DP 29) for FO rabbits, on DP49 for F1 pups not selected for continued evaluation, sfter completion of mating for F1 rabbits, and on DG 29 for F1 rabbits on continued evaluation of F2 litter. There was no thalidomide-related mortality in FO and F1 rabbits. One FO doe at 30 and 150 mg/kg and 2 at 500 mg/kg aborted. Maternal FO rabbits had reductions in feed consumption but no body weight gain during the gestation and lactation periods for 150 and 500 mg/kg. The numbers of does with stillborn and all pups dyving from DP 1-4 was increased at 150 and 500 mg/kg. Mean number of liverborn (litter size) and percentage of live pups were decreased at 500 mg/kg. A significantly increased number of pups died at 150 and 500 mg/kg, resulting in a reduced viability index and decreased litter size. There were some F1 male and female bodyweight reductions at 150 and 500 mg/kg postweaning with no changein feed consumption. F1 Caesarean-sectioning and litter observations were normal. Fertility of F1 offspring was not affected by maternal doses of thalidomide, but the pregnancy index may have been reduced by the 500 mg/kg maternal thalidomide dose. There was an apparent dose-related increased in splayed limbs in F1 pups. Splaving has been reported in New Zealand Whith rabbits and may be a recessive trait. The splay could be caused by the nerve and muscle fiber degeneration and skeletal muscle atrophy observed in some pups. It could also be due to the decreased in litter size, resulting in fewer pups per litter for nursing, leading to rapid weight gain and a failure of the pups to support this weight. No F@ fetal gross external alterations were observed. (AU). Descriptors: COELHOS/anorm COELHOS/embriol COELHOS/cresc TALIDOMIDA/admin TALIDOMIDA/ef adv TALIDOMIDA/farmacol - ABORTO ANIMAL/etiol  PESO AO NASCER/ef drogas Limits: COELHOS Location: BR191.1; 00953/s

2 / 11

HANSEN

select to print

Id: 18426 Author: Teo, Steve K; Colburn, Wayne A; Tracewell, William G; Kook, Karin A; Stirling, David I; Jaworsky, Markian S; Scheffer, Michael A; Thomas, Steve D; Laskin, Oscar L Title: Clinical pharmacokinetics of thalidomide ..- Source: s.l; s.n; 2004. 17 p. ilus, tab, graf. Abstract: Thalidomide is a racemic glutamic acid derivative approved in the US for erythema nodosum leprosum, a complication of leprosy. In addition, its use in various inflammatory and oncologic conditions in being investigated. Thalidomide interconverts between the (R)- and (S)-enantiomers in plasma, with protein binding of 55% and 65%, respectively. More than 90% of the absorbed drug is excreted in the urine and faeces within 48 hours. Thalidomide is minimally metabolised by the liver, but is spontaneously hydrolysed into numerous renally excreted products. After a single oral dose of thalidomide 200mg (as the US-approved capsule formulation) in healthy volunteers, absorption is slow and extensive, resulting in a peak concentration (Cmax) of 1-2mg/L at 3-4 hours after administration, absorption lag time of 30 minutes, total exposure (AUCoo) of 18mg - h/L, apparent elimination half-life of 6 hours and apparent systemic clearence of 10 L/H. Thalidomide pharmacokinetics are best described by a one-comportment model with first-order absorption and elimination. Because of the low solubility of the drug in the gastrointestinal tract, thalidomide exhibits absorption rate-limited pharmacolinetics (the 'flip-flop' phenomenon), with its elimination rate being faster than in absorption rate. The apparent elimination half-life of 6 hours therefore represents absorption, not elimination. The 'true' apparent volume of distribution was estimated to be 16L by use of the faster elimination-rate half-life. Multiple doses of thalidomide 200 mg/day over 21 days cause no change in the pharmacokinetics, with a steady-state Cmax (Cssmax) of 1.2 mg/L. Simulation of 400 and 800 mg/day also shows no accululation, with Css of 3.5 and 6.0 mg/L, respectively. Multiple-dose studies in cancer patients show pharmacokinetics comparable with those in healthy populations at similar dosages. Thalidomide exhibits a dose-proportional increase in AUC at doses from 50 to 400mg. Because of the low solubility of thalidomide Cmax is less than proportional to dose, and tmax is prolonged with increasing dose. Age, sex and smoking have no effect on the pharmacokinetics of thalidomide, and the effect of food is minimal. Thalidomide does not alter the pharmacokinetics of oral contraceptives, and is also unlikely to interact with warfarin and grapefruit juice. Since thalidomide is mainly hydrolysed and passively excreted, its pharmacokonetics are not expected to change in patients with impaired liver...(AU). Descriptors: TALIDOMIDA/admin TALIDOMIDA/sint quim TALIDOMIDA/contra TALIDOMIDA/hist TALIDOMIDA/isol TALIDOMIDA/farmacocin TALIDOMIDA/normas TALIDOMIDA/tox TALIDOMIDA/uso terap TALIDOMIDA/metab - ERITEMA NODOSO HANSENICO/quimioter  ERITEMA NODOSO/etiol  SINDROME DE IMUNODEFICIÊNCIA ADQUIRIDA FELINA/terap  ADMINISTRACAO ORAL  INTERACOES DE MEDICAMENTOS/fisiol  RIFAMPINA/antag  FENOBARBITAL/antag  CIMETIDINA/antag  DILTIAZEM/antag  WARFARIN/antag Limits: HUMANO Location: BR191.1; 00948/s

3 / 11

HANSEN

select to print

Id: 14885 Author: Terencio de las Aguas, José. Title: Seis años de experiencia con talidomida. Source: Fontilles - Revista de Leprología;8(5):587-598, May.-Ago. 1972. graf. Abstract: Después de seis años de experiencia con talidomida en el tratamiento de las leprorreacciones se exponen los resultados. Han sido tratados un total de 165 enfermos separados en dos grupos, el primer de 100 enfermos con cuadro típico reaccional y el segundo de 65 con reacciones muy discretas, o cuadros monosintomáticos reaccionales. En el grupo I, 62 hombres y 38 mujeres, tuvieron un total de 390 reacciones, 236 en varones y 154 en hembras. El éxito fue total en todos y las dosis idóneas iniciales fueron de 300 a 400 mg. En los enfermos tratados anteriormente en corticosteroides fue necesario dosis de 500-600 mg., doble o triple de días para la desaparición y más tiempo con dosificación de sostén. Los dos casos tuberculoides reaccionales mejoraron en sus lesiones cutáneas muy lentamente. En el grupo II de enfermos con polineuritis no obedecieron a esta terapéutica. La tolerancia fue buena. Se han utilizado diversas imidas cíclicas y sus resultados han sido poco alentadores. Se hacen consideraciones sobre la forma de actuar la droga, bein como estimulante hipofisario o inmunosupresor. (AU). Descriptors: HANSENIASE TALIDOMIDA/admin TALIDOMIDA/anal Limits: RELATO DE CASO Electronic Medium: http://www.ilsl.br Location: BR191.1

4 / 11

HANSEN

select to print

Id: 14810 Author: Terencio de las Aguas, José; Contreras Dueñas, Félix. Title: Primeros resultados del tratamiento de las leprorreacciones con talidomida. Source: Revista de Leprologia Fontilles;6(5):449-455, Ene.-Jun. 1966. graf. Abstract: Se han tratado seis enfermos lepromatosos, dos hombres y cuatro mujeres, con leprorreacciones frecuentes durante varios años, con talidomida, en dosis iniciciales máximas de 100 mgr., descendiendo paulatinamente a 50 y 25 mgr., con la mejoría del cuadro. La leprorreacción desapació en cinco enfermos, teniéndose que suspender después de vários días este tratamiento en un enfermo por accidente alérgico de mediana intensidad. El tiempo de desaparición de la fiebre oscila entre dos y 11 días. en uno de los casos la enferma llevaba cuatro años en estado reaccional continuo y corticosteroides. (AU). Descriptors: HANSENIASE HANSENIASE/clas HANSENIASE/compl HANSENIASE/diag HANSENIASE/quimioter HANSENIASE/prev TALIDOMIDA/admin Electronic Medium: http://www.ilsl.br Location: BR191.1

5 / 11

HANSEN

select to print

Id: 14641 Author: Penna, Gerson Oliveira Title: Hanseníase e o uso da talidomida no eritema nodoso hansênico: perspectivas de pesquisas ?- Source: Brasília; s.n; 2002. viii, 104 p. ilus, mapas, graf. Thesis: Present for Universidade de Brasília. Faculdade de Medicina presented for the degree Doutor. Abstract: Hanseníase segue sendo um grande problema de saúde pública e, episódios de eritema nodoso hansênico (ENH) são eventos agudos freqüentes que podem ocorrer antes, durante e após o tratamento poliquimioterápico padrão (PQT). No Brasil, a talidomida (μ-N-phitalodomidoglutarimide) vem sendo utilizada no tratamento do ENH desde a década de 60, sob regulação estrita do Ministério da Saúde. Nos últimos dez anos o uso da talidomida foi expandido para doenças associadas a aids, doença enxerto versus hospedeiro, artrite reumatóide, lupus e mieloma múltiplo. Talidomida tem feito teratogênico em humanos o que provocou sua retirada do mercado em muitos países em décadas passadas. Recentemente vem havendo um renovado interesse em talidomida com agente terapêutico anti-inflamatório e imuno-modulador. Talidomida é capaz de inibir a ação de potente citocina pró-inflamatória TNF-μ in vitro e in vivo. A avaliação de regimes terapêuticos, dosegens, com ou sem retirada gradual da droga (desmame) é crucial para uma boa prática clínica. Procedemos uma revisão sistemática dos ensaios clínicos publicados para tentar acessar a eficácia e os efeitos colaterais da talidomida no ENH. Este manuscrito também descreve a metodologia empregada em um ensaio clínico que esta sendo conduzido por instituições acadêmicas, patrocinado pela industria farmacêutica, para avaliar a resposta terapêutica e a necessidade de desmame da talidomida particularmente naqueles pacientes elegíveis para inclusão(AU). Descriptors: HANSENIASE/quimioter HANSENIASE/prev ERITEMA NODOSO - TALIDOMIDA/admin  TALIDOMIDA/uso diag Location: BR191.1; WC335.102.60, P381h

6 / 11

HANSEN

select to print

Id: 13829 Author: Meisels-Navon, LIora; Sheskin, Jacobo. Title: Revisión de algunos aspectos, comunes y cantrastantes, en rehabilitación de damnificados y beneficiados por la talidomida. Source: Fontilles - Revista de Leprología;16(3):287-295, Sep.-Dic. 1987. . Abstract: Se estudian los aspectos físicos, sociales, psicológicos y familiares en la reahabilitación de damnificados e auxiliados por la talidomida. El análise de estos aspectos, comunes a ambos grupos los unos, contrastantes los otros, permitirá dar un paso más hacia la reintegración del hanseniano a la sociedad. (AU). Descriptors: HANSENIASE/quimioter TALIDOMIDA/admin TALIDOMIDA/ef adv Location: BR191.1

7 / 11

HANSEN

select to print

Id: 12766 Author: São Paulo(Estado). Secretaria de Politicas de Saúde*. Title: Portaria conjunta n§ 25, de 30 de janeiro de 2002, sobre o acesso à Talidomida aos usuários do SUS ..- Source: São Paulo; s.n; 2002. 10 p. . Descriptors: TALIDOMIDA DOENÇA ENXERTO-HOSPEDEIRO LUPUS ERITEMATOSO SISTEMICO MIELOMA MULTIPLO POLITICA DE SAUDE Location: BR191.1; 0555/d.a

8 / 11

HANSEN

select to print

Id: 11516 Author: Liao, Adolfo Wenjaw; Ruano, Rodrigo; Bunduki, Victor; Miyadahira, Seizo; Zugaib, Marcelo Title: Talidomida: aspectos atuais em obstetrícia ?- Source: São Paulo; s.n; 1999. 4 p. tab, graf. Descriptors: TALIDOMIDA TALIDOMIDA TALIDOMIDA TALIDOMIDA TALIDOMIDA TALIDOMIDA ANORMALIDADES INDUZIDAS POR DROGAS HANSENIASE COMPLICAÇOES NA GRAVIDEZ LUPUS ERITEMATOSO SISTEMICO ERITEMA NODOSO TERATOGENIOS GRAVIDEZ CUIDADOS MEDICOS Location: BR191.1; 08411/s

9 / 11

HANSEN

select to print

Id: 11017 Author: Partida-Sanchez, S; Favila-Castillo, L; Pedraza-Sanchez, S; Gomez-Melgar, M; Saul, A; Estrada-Parra, S; Estrada-Garcia, I Title: IgG antibody subclasses, tumor necrosis factor and IFN-gamma levels in patients with type II lepra reaction in thalidomide treatment ..- Source: s.l; s.n; 1998. 7 p. tab, graf. Descriptors: ADOLESCENCIA ANTICORPOS ANTIBACTÉRIAS ANTICORPOS ANTIBACTÉRIAS INTERPRETAÇAO ESTATISTICA DE DADOS ERITEMA NODOSO INTERFERON TIPO II INTERFERON TIPO II LEPROSTATICOS LEPROSTATICOS LEPROSTATICOS HANSENIASE DIMORFA HANSENIASE DIMORFA HANSENIASE TUBERCULOIDE HANSENIASE TUBERCULOIDE MYCOBACTERIUM LEPRAE TALIDOMIDA TALIDOMIDA TALIDOMIDA FATOR DE NECROSE TUMORAL/ME IMUNOGLOBULINA M/BL/CL FATOR DE NECROSE TUMORAL/*ME Limits: ESTUDO COMPARATIVO Location: BR191.1; 07285/s

10 / 11

HANSEN

select to print

Id: 10168 Author: Kaplan, Gilla Title: Cytokine regulation of disease progression in leprosy and tuberculosis ..- Source: s.l; s.n; 1994. 5 p. . Descriptors: HANSENIASE LEPROMATOSA HANSENIASE LEPROMATOSA INFECÇOES OPORTUNISTAS RELACIONADAS COM A AIDS INFECÇOES OPORTUNISTAS RELACIONADAS COM A AIDS CITOCINAS ERITEMA NODOSO ERITEMA NODOSO HIV-1 IMUNIDADE CELULAR INJEÇOES INTRADÉRMICAS INTERFERON TIPO II INTERFERON TIPO II TALIDOMIDA TUBERCULOSE TUBERCULOSE TUBERCULOSE FATOR DE NECROSE DE TUMOR FATOR DE NECROSE DE TUMOR Location: BR191.1; 07081/s

11 / 11

HANSEN

select to print

Id: 6771 Author: Convit, Jacinto; Browne, Stanley G; Languillon, J; Pettit, J. H; Ramanujan, K; Sagher, F; Sheskin, J; Lima, Lauro de Souza; Tarabini, G; Tolentino, J. G; Waters, M. F. R; Bechelli, Luiz Marino; Martinez Dominguez, V Title: Therapy of leprosy ..- Source: s.l; s.n; 1970. 6 p. . Descriptors: HANSENIASE HANSENIASE - SULFONAS  SULFONAS  TALIDOMIDA  TALIDOMIDA Location: BR191.1; 03901/s

---

page 1 de 1

Refine the search

Database : HANSEN

Advanced form

Search for : Free form

		Search	in field
1			WordsTitle wordsAbstract wordsAuthorInstitutional authorSubject descriptorLimitsLanguageCountry, year publicationJournalType of literatureBibliographic levelMonography in seriesPublication typeConferenceUnique identifierLocationElectronic supportEntry dateRecord type
2	and or and not		WordsTitle wordsAbstract wordsAuthorInstitutional authorSubject descriptorLimitsLanguageCountry, year publicationJournalType of literatureBibliographic levelMonography in seriesPublication typeConferenceUnique identifierLocationElectronic supportEntry dateRecord type
3	and or and not		WordsTitle wordsAbstract wordsAuthorInstitutional authorSubject descriptorLimitsLanguageCountry, year publicationJournalType of literatureBibliographic levelMonography in seriesPublication typeConferenceUnique identifierLocationElectronic supportEntry dateRecord type

Search engine: iAH powered by WWWISIS

IAH - © BIREME/PAHO/WHO Latin American and Caribbean Center on Health Sciences Information